Table 1. Sample demographics.
| HV | NAPD | Statistics (P-value, test statistic) | |
|---|---|---|---|
| Gender | (1, 0a) | ||
| Male | 8 | 8 | |
| Female | 4 | 4 | |
| Age | 48.08 (9.94) | 44.67 (11.24) | (0.44, −0.79b) |
| Educationc | 5.83 (1.4) | 5.33 (1.44) | (0.4, 0.86a) |
| Smoking | (0.38, 0.54a) | ||
| Nonsmoker | 11 | 10 | |
| Smoker | 1 | 2 | |
| Cannabis lifetimed | 0.23 (0.83) | 0.67 (1.23) | (0.31, 1.04) |
| Other drugs lifetimed,e | 0 (0) | 0.01 (0.04) | (0.31, 1.04) |
| Injected radioligand (MBq) | 189.83 (8.2) | 187.92 (10.86) | (0.4, −0.85b) |
| Specific activity (GBq) | 2611.42 (872.96) | 2146.25 (1198.6) | (0.98, −0.03b) |
| Current symptomsf | — | 11.83 (3.93) | — |
| Years off AP | — | 7.09 (4.96) | — |
| Cumulative haloperidol equivalentsg | — | 4303.07 (12 280.64) | — |
Abbreviations: AP, antipsychotics; HV, healthy volunteer; NAPD, non-affective psychotic disorder.
a
Chi2 test.
b
T-test.
c
Highest finished education, scored on a scale ranging from 1 (primary school) to 8 (Masters degree).
d
Lifetime use scored on a scale ranging from 1 (one to five times) to 8 (>100 times).
e
Stimulants, sedatives, opiates, cocaine, psychedelics, XTC, MDMA, PCP and inhalants subscales.
f
Positive subscale of the Positive and Negative Syndrome Subscale (PANSS).
g
Cumulative haloperidol equivalents were calculated by converting the weekly antipsychotics dose to haloperidol equivalents and multiplying it by the number of weeks the antipsychotics were taken.